916 reports of this reaction
3.1% of all RALTEGRAVIR reports
#5 most reported adverse reaction
PAIN is the #5 most commonly reported adverse reaction for RALTEGRAVIR, manufactured by Merck Sharp & Dohme LLC. There are 916 FDA adverse event reports linking RALTEGRAVIR to PAIN. This represents approximately 3.1% of all 29,953 adverse event reports for this drug.
Patients taking RALTEGRAVIR who experience pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PAIN is moderately reported among RALTEGRAVIR users, representing a notable but not dominant share of adverse events.
In addition to pain, the following adverse reactions have been reported for RALTEGRAVIR:
The following drugs have also been linked to pain in FDA adverse event reports:
PAIN has been reported as an adverse event in 916 FDA reports for RALTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
PAIN accounts for approximately 3.1% of all adverse event reports for RALTEGRAVIR, making it a notable side effect.
If you experience pain while taking RALTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.